SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma’s arm receives marketing authorization for Baclofen

19 Mar 2025 Evaluate

Marksans Pharma’s wholly owned subsidiary in UK -- Relonchem has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK Medicines and Healthcare Products Regulatory Agency (UK MHRA). 

Earlier, Relonchem had received Marketing Authorization for the product Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).

Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.


Marksans Pharma Share Price

197.90 -5.25 (-2.58%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×